This is a Validated Antibody Database (VAD) review about human MDM2, based on 126 published articles (read how Labome selects the articles), using MDM2 antibody in all methods. It is aimed to help Labome visitors find the most suited MDM2 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
MDM2 synonym: ACTFS; HDMX; LSKB; hdm2

Santa Cruz Biotechnology
mouse monoclonal (SMP14)
  • western blot; mouse; 1:200; loading ...; fig 2b
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on mouse samples at 1:200 (fig 2b). Adv Sci (Weinh) (2022) ncbi
mouse monoclonal (SMP14)
  • western blot; human; loading ...; fig 8b
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc965) was used in western blot on human samples (fig 8b). Sci Adv (2021) ncbi
mouse monoclonal (SMP14)
  • western blot; human; 1:100; loading ...; fig 3c
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on human samples at 1:100 (fig 3c). Cancers (Basel) (2021) ncbi
mouse monoclonal (SMP14)
  • western blot; human; 1:500; loading ...; fig 4a
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, Sc-965) was used in western blot on human samples at 1:500 (fig 4a). Front Oncol (2021) ncbi
mouse monoclonal (SMP14)
  • western blot; human; loading ...; fig 4a
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on human samples (fig 4a). BMC Cancer (2021) ncbi
mouse monoclonal (SMP14)
  • western blot; human; 0.2 ug/ml; loading ...; fig 7e
Santa Cruz Biotechnology MDM2 antibody (Santa, sc965) was used in western blot on human samples at 0.2 ug/ml (fig 7e). Commun Biol (2020) ncbi
mouse monoclonal (SMP14)
  • western blot; human; loading ...; fig 1c
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, SMP14) was used in western blot on human samples (fig 1c). PLoS Pathog (2020) ncbi
mouse monoclonal (SMP14)
  • western blot; human; 1:1000; loading ...; fig 5a, 5b
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples at 1:1000 (fig 5a, 5b). Nat Commun (2019) ncbi
mouse monoclonal (SMP14)
  • western blot; mouse; loading ...; fig 4c
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on mouse samples (fig 4c). Cancer Cell (2019) ncbi
mouse monoclonal (SMP14)
  • western blot; human; loading ...; fig 1a
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples (fig 1a). J Biol Chem (2019) ncbi
mouse monoclonal (HDM2-323)
  • western blot; human; loading ...; fig 6a
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, HDM2-323) was used in western blot on human samples (fig 6a). Toxicol Appl Pharmacol (2018) ncbi
mouse monoclonal (SMP14)
  • western blot; human; loading ...; fig s4e
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on human samples (fig s4e). Cell Metab (2018) ncbi
mouse monoclonal (SMP14)
  • immunoprecipitation; human; fig 2b
  • western blot; human; 1:500; loading ...; fig s4
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, SMP14) was used in immunoprecipitation on human samples (fig 2b) and in western blot on human samples at 1:500 (fig s4). Oncogene (2018) ncbi
mouse monoclonal (SMP14)
  • immunohistochemistry - paraffin section; mouse; fig 8a
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology Inc, sc-965) was used in immunohistochemistry - paraffin section on mouse samples (fig 8a). J Exp Med (2018) ncbi
mouse monoclonal (SMP14)
  • immunohistochemistry - paraffin section; human; 1:50; fig 6d
  • immunoprecipitation; human; loading ...; fig 4g
  • immunocytochemistry; human; 1:100; loading ...; fig 4d
  • western blot; human; 1:100; loading ...; fig 3f
In order to identify XBP1-u as a regulator of the MDM2/p53 function, Santa Cruz Biotechnology MDM2 antibody (SantaCruz, sc-965) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 6d), in immunoprecipitation on human samples (fig 4g), in immunocytochemistry on human samples at 1:100 (fig 4d) and in western blot on human samples at 1:100 (fig 3f). Sci Adv (2017) ncbi
mouse monoclonal (SMP14)
  • immunoprecipitation; human; loading ...; fig 4a
Santa Cruz Biotechnology MDM2 antibody (santa, SMP14) was used in immunoprecipitation on human samples (fig 4a). Oncogene (2017) ncbi
mouse monoclonal (SMP14)
  • western blot; human; loading ...; fig 6
Santa Cruz Biotechnology MDM2 antibody (SC Biotech, SMP14) was used in western blot on human samples (fig 6). Oncotarget (2017) ncbi
mouse monoclonal (SMP14)
  • immunohistochemistry - frozen section; mouse; 1:50; loading ...; fig 1c
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, SMP14) was used in immunohistochemistry - frozen section on mouse samples at 1:50 (fig 1c). Dev Biol (2017) ncbi
mouse monoclonal (SMP14)
  • western blot; human; loading ...; fig 8a
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples (fig 8a). J Cell Physiol (2017) ncbi
mouse monoclonal (D-12)
  • western blot; human; 1:500; loading ...; fig 1a
Santa Cruz Biotechnology MDM2 antibody (SantaCruz, sc-5304) was used in western blot on human samples at 1:500 (fig 1a). Oncogene (2017) ncbi
mouse monoclonal (SMP14)
  • western blot; mouse; 1:750; loading ...; fig 2b
In order to investigate the effects of a CDK4/6 inhibitor on the senescence-associated secretory phenotype, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on mouse samples at 1:750 (fig 2b). Mol Cancer Res (2017) ncbi
mouse monoclonal (SMP14)
  • western blot; human; 1:200; loading ...; fig 2b
In order to elucidate the contribution of MDM2 expression to retinoblastoma tumorigenesis, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples at 1:200 (fig 2b). Oncogene (2017) ncbi
mouse monoclonal (D-12)
  • western blot; human; 1:500; loading ...; fig 2
In order to use polo-like kinase 1 inhibitors for a rationally designed chemotherapy protocols to treat patients with metastasized retinoblastoma, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology Inc., sc5304) was used in western blot on human samples at 1:500 (fig 2). Clin Exp Ophthalmol (2017) ncbi
mouse monoclonal (SMP14)
  • immunohistochemistry - paraffin section; human; tbl 1
In order to determine the concordance between two methods to detect cases of atypical lipomatous tumor/well-differentiated liposarcoma, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in immunohistochemistry - paraffin section on human samples (tbl 1). Am J Surg Pathol (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; mouse; 1:200; fig s4
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on mouse samples at 1:200 (fig s4). Nat Commun (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig 6
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples (fig 6). Sci Rep (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; dogs; 1:1000; loading ...; fig 2
In order to report the effect of enrofloxacin addition to either doxorubicin or carboplatin on osteosarcoma cell viability and examine p53 status, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, 965) was used in western blot on dogs samples at 1:1000 (fig 2). Vet Comp Oncol (2017) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig s3b
In order to investigate the role of growth hormone in colon cancer, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples (fig s3b). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (SMP14)
  • immunoprecipitation; human; fig 3
  • western blot; human; fig 1
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in immunoprecipitation on human samples (fig 3) and in western blot on human samples (fig 1). J Biol Chem (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig 3
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on human samples (fig 3). Cell Death Dis (2016) ncbi
mouse monoclonal (SMP14)
  • immunohistochemistry - paraffin section; human; loading ...; fig s9d
  • immunoprecipitation; human; loading ...; fig 6d
  • western blot; human; loading ...; fig 5e
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in immunohistochemistry - paraffin section on human samples (fig s9d), in immunoprecipitation on human samples (fig 6d) and in western blot on human samples (fig 5e). Oncogene (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; human; loading ...; fig s3e
Santa Cruz Biotechnology MDM2 antibody (SantaCruz, SMP14) was used in western blot on human samples (fig s3e). Science (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig 5
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples (fig 5). Oncotarget (2016) ncbi
mouse monoclonal (SMP14)
  • immunocytochemistry; human; 1:100; fig s2
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in immunocytochemistry on human samples at 1:100 (fig s2). Oncotarget (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; mouse; loading ...; fig ev1g
  • western blot; human; loading ...; fig 1b
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, SMP14) was used in western blot on mouse samples (fig ev1g) and in western blot on human samples (fig 1b). EMBO Rep (2016) ncbi
mouse monoclonal (D-7)
  • western blot; human; loading ...; fig 3c
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-13161) was used in western blot on human samples (fig 3c). Oncogene (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig 4e
Santa Cruz Biotechnology MDM2 antibody (santa cruz, sc-965) was used in western blot on human samples (fig 4e). J Biol Chem (2016) ncbi
mouse monoclonal (SMP14)
  • immunocytochemistry; human; loading ...; fig 3a
  • western blot; human; loading ...; fig 7a
Santa Cruz Biotechnology MDM2 antibody (SantaCruz, SC-965) was used in immunocytochemistry on human samples (fig 3a) and in western blot on human samples (fig 7a). Oncogene (2016) ncbi
mouse monoclonal (SMP14)
  • ELISA; human; 1:50; fig 7
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in ELISA on human samples at 1:50 (fig 7). Oncotarget (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; human; 1:1000; fig 3
In order to investigate MDM4 exon 6 skipping by antisense oligionucleotides and its affect on inhibiting tumor growth, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on human samples at 1:1000 (fig 3). J Clin Invest (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig s3
In order to examine the relationship between PML IV and ARF, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, SMP14) was used in western blot on human samples (fig s3). Proc Natl Acad Sci U S A (2015) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig 5
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples (fig 5). Aging (Albany NY) (2015) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig 3
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on human samples (fig 3). Oncotarget (2015) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig 4
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples (fig 4). Nucleic Acids Res (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig 3
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples (fig 3). Mol Cancer Ther (2015) ncbi
mouse monoclonal (SMP14)
  • immunoprecipitation; human; fig 3
  • immunocytochemistry; human; fig 4
  • western blot; human; fig 2
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in immunoprecipitation on human samples (fig 3), in immunocytochemistry on human samples (fig 4) and in western blot on human samples (fig 2). Oncotarget (2015) ncbi
mouse monoclonal (SMP14)
  • western blot; human; 1:1000; loading ...; fig 4b
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples at 1:1000 (fig 4b). Oncotarget (2015) ncbi
mouse monoclonal (SMP14)
  • western blot; mouse; 1:200; fig 3
In order to study how regenerative progenitors can be turned into terminally differentiated skeletal muscle cells, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on mouse samples at 1:200 (fig 3). Nat Commun (2015) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig 6a
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, SMP14) was used in western blot on human samples (fig 6a). Cell Death Dis (2015) ncbi
mouse monoclonal (SMP14)
  • western blot; mouse; 1:500; fig 1
In order to report a role for p53 in regulating the membrane phospholipids composition, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on mouse samples at 1:500 (fig 1). Oncotarget (2015) ncbi
mouse monoclonal (SMP14)
  • immunoprecipitation; human; loading ...; fig 2D
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, SMP14) was used in immunoprecipitation on human samples (fig 2D). Oncotarget (2015) ncbi
mouse monoclonal (SMP14)
  • western blot; human
In order to study the role of p53 stabilization in the effects of chemotherapy drugs, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on human samples . Oncogene (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; human; fig 2
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, SMP14) was used in western blot on human samples (fig 2). Oncotarget (2015) ncbi
mouse monoclonal (SMP14)
  • western blot; human; 1:1000
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on human samples at 1:1000. J Neuroimmunol (2014) ncbi
mouse monoclonal (SMP14)
  • western blot; human
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on human samples . Oncotarget (2014) ncbi
mouse monoclonal (SMP14)
  • western blot; human; 1:500; tbl 1
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples at 1:500 (tbl 1). Methods Mol Biol (2015) ncbi
mouse monoclonal (SMP14)
  • western blot; human
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on human samples . Cell Div (2014) ncbi
mouse monoclonal (SMP14)
  • western blot; human
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, SMP14) was used in western blot on human samples . Oncotarget (2014) ncbi
mouse monoclonal (SMP14)
  • immunoprecipitation; human
Santa Cruz Biotechnology MDM2 antibody (Santa, sc-965AC) was used in immunoprecipitation on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (SMP14)
  • western blot; human
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in western blot on human samples . J Biol Chem (2014) ncbi
mouse monoclonal (SMP14)
  • immunoprecipitation; human; fig 4b
  • western blot; human; fig 4b
Santa Cruz Biotechnology MDM2 antibody (Santa, Sc-965) was used in immunoprecipitation on human samples (fig 4b) and in western blot on human samples (fig 4b). Oncotarget (2014) ncbi
mouse monoclonal (SMP14)
  • western blot; human
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, SMP-14) was used in western blot on human samples . Mol Cell Biol (2014) ncbi
mouse monoclonal (SMP14)
  • immunoprecipitation; human; 5 ug
  • western blot; human
In order to evaluate large subunit ribosomal proteins as therapeutic targets for melanoma, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-965) was used in immunoprecipitation on human samples at 5 ug and in western blot on human samples . Pigment Cell Melanoma Res (2014) ncbi
mouse monoclonal (D-12)
  • western blot; human
In order to evaluate large subunit ribosomal proteins as therapeutic targets for melanoma, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, sc-5304) was used in western blot on human samples . Pigment Cell Melanoma Res (2014) ncbi
mouse monoclonal (SMP14)
  • western blot; human
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, SMP14) was used in western blot on human samples . Mol Cell Biochem (2014) ncbi
mouse monoclonal (SMP14)
  • immunoprecipitation; human; 1:500
  • immunocytochemistry; human; 1:500
  • western blot; human; 1:500
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, SC-965) was used in immunoprecipitation on human samples at 1:500, in immunocytochemistry on human samples at 1:500 and in western blot on human samples at 1:500. Biochim Biophys Acta (2014) ncbi
mouse monoclonal (SMP14)
  • immunoprecipitation; mouse
Santa Cruz Biotechnology MDM2 antibody (Santa, sc-965) was used in immunoprecipitation on mouse samples . Cancer Res (2013) ncbi
mouse monoclonal (SMP14)
  • western blot; human; 1:500; fig 1
In order to develop a neuregulin-1 overexpressing transgenic mouse model of neurofibroma-malignant peripheral nerve sheath tumor progression, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, sc-965) was used in western blot on human samples at 1:500 (fig 1). Am J Pathol (2013) ncbi
mouse monoclonal (HDM2-323)
  • western blot; human
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, 56154) was used in western blot on human samples . Oncogene (2014) ncbi
mouse monoclonal (SMP14)
  • western blot; human
Santa Cruz Biotechnology MDM2 antibody (Santa Cruz, SMP14) was used in western blot on human samples . Cell Death Differ (2013) ncbi
mouse monoclonal (SMP14)
  • western blot; human
In order to investigate the effect of MDM2 oncoprotein on the expression of p63, Santa Cruz Biotechnology MDM2 antibody (Santa Cruz Biotechnology, smp14) was used in western blot on human samples . J Biol Chem (2002) ncbi
Invitrogen
mouse monoclonal (IF2)
  • western blot; human; loading ...; fig 5a
In order to elucidate a mutually regulatory relationship between signal transducer and activator of transcription 5 and nucleophosmin, Invitrogen MDM2 antibody (Invitrogen, 33-7100) was used in western blot on human samples (fig 5a). Cell Death Dis (2016) ncbi
domestic rabbit recombinant (4H26L4)
  • western blot; human; loading ...; fig 1
In order to report the effects of NVP-CGM097 on the p53wildtype GOT1 cells, Invitrogen MDM2 antibody (Invitrogen, 700555) was used in western blot on human samples (fig 1). Neuroendocrinology (2018) ncbi
domestic rabbit recombinant (4H26L4)
  • western blot; human; loading ...; fig 3a, b
In order to show a MDM2/p53-mediated rapamycin resistance in human renal cancer cells, Invitrogen MDM2 antibody (Pierce, 4H26L4) was used in western blot on human samples (fig 3a, b). Cell Physiol Biochem (2016) ncbi
domestic rabbit recombinant (4H26L4)
  • western blot; human; 1:300; loading ...; fig 2b
In order to elucidate the contribution of MDM2 expression to retinoblastoma tumorigenesis, Invitrogen MDM2 antibody (InVitrogen, 700555) was used in western blot on human samples at 1:300 (fig 2b). Oncogene (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 6e
In order to study how SMG7 regulates p53 stability, Invitrogen MDM2 antibody (Thermo Scientific, PA5-13008) was used in western blot on human samples (fig 6e). Cell Discov (2016) ncbi
mouse monoclonal (IF2)
  • western blot; human; 1:500; loading ...; fig 2b
In order to find that USP2 stabilizes Mdm2 which antagonizes p53 activity, Invitrogen MDM2 antibody (Invitrogen, 33-7100) was used in western blot on human samples at 1:500 (fig 2b). Oncotarget (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; fig 6
In order to determine the promotion of genomic and phenotypic changes in glioblastoma cells by temozolomide, Invitrogen MDM2 antibody (Thermo Fisher Scientific, PA5-11353) was used in western blot on human samples (fig 6). Cancer Cell Int (2016) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry; human
In order to investigate the frequency and contribution of HMGA2, CDK4, and JUN to dedifferentiated liposarcomas and atypical lipomatous tumors/well-differentiated liposarcomas, Invitrogen MDM2 antibody (Zymed Laboratories, IF2) was used in immunohistochemistry on human samples . Mod Pathol (2015) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:50
In order to characterize a primary myxoid liposarcoma with chondroid and osseous components, Invitrogen MDM2 antibody (Invitrogen, IF2) was used in immunohistochemistry - paraffin section on human samples at 1:50. Appl Immunohistochem Mol Morphol (2015) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:50
Invitrogen MDM2 antibody (Invitrogen, clone IF2) was used in immunohistochemistry - paraffin section on human samples at 1:50. Hum Pathol (2015) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:100
Invitrogen MDM2 antibody (Zymed, IF2) was used in immunohistochemistry - paraffin section on human samples at 1:100. Mod Pathol (2015) ncbi
mouse monoclonal (IF2)
  • western blot; human; fig 5
In order to report proof-of-principle studies targeting CDH17 for treating gastric cancer, Invitrogen MDM2 antibody (Zymed, 33-7100) was used in western blot on human samples (fig 5). PLoS ONE (2013) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:100
Invitrogen MDM2 antibody (Invitrogen Zymed, IF2) was used in immunohistochemistry - paraffin section on human samples at 1:100. World Neurosurg (2014) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:100; tbl 1.
In order to discuss markers that distinguish between different subtypes of osteosarcomas, Invitrogen MDM2 antibody (Zymed Laboratories, IF2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (tbl 1.). Am J Surg Pathol (2012) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry; human; 1:25; fig 6
In order to examine expression of MDM2-CDK4 in low-grade osteosarcomas and fibrous or fibro-osseous lesions of the bone or paraosseous soft tissue, Invitrogen MDM2 antibody (Zymed, IF2) was used in immunohistochemistry on human samples at 1:25 (fig 6). Mod Pathol (2011) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:100; fig 2
In order to use 9 cases of well-differentiated/dedifferentiated liposarcoma to characterize unappreciated features, Invitrogen MDM2 antibody (Zymed, IF2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2). Am J Surg Pathol (2010) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:100; fig 4
In order to explore the use of MDM2 and CDK4 for the histological diagnosis of low-grade osteosarcoma, Invitrogen MDM2 antibody (Zymed, IF2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 4). Mod Pathol (2010) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:100
In order to report genetic changes in dedifferentiated liposarcomas, Invitrogen MDM2 antibody (Zymed, IF2) was used in immunohistochemistry - paraffin section on human samples at 1:100. Mod Pathol (2009) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:50; fig 1
In order to identify immunohistochemical markers to aid chondroid tumor diagnosis, Invitrogen MDM2 antibody (Zymed, 1F2) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 1). APMIS (2009) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry; human; fig 2
In order to discuss a rare presentation of a lipoleiomyosarcoma and review the method of pathologic diagnosis, Invitrogen MDM2 antibody (Zymed, IF2) was used in immunohistochemistry on human samples (fig 2). Am J Clin Oncol (2009) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry; human; fig 2
In order to discuss the properties of desmoid tumors, Invitrogen MDM2 antibody (Zymed, IF2) was used in immunohistochemistry on human samples (fig 2). JOP (2008) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:100
In order to assess if immunostaining for PPAR-gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas, Invitrogen MDM2 antibody (Zymed, IF2) was used in immunohistochemistry - paraffin section on human samples at 1:100. Mod Pathol (2008) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:100; tbl 1
In order to present a unique case of relapsing retroperitoneal dedifferentiated liposarcoma with alpha-fetoprotein ectopic production, Invitrogen MDM2 antibody (Zymed, IF2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (tbl 1). Virchows Arch (2006) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 1
In order to present the case of a patient with a rare atypical lipomatous tumor with spindle cell features, Invitrogen MDM2 antibody (Zymed, IF2) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 1). Virchows Arch (2005) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - frozen section; human; 1:100; fig 3
In order to characterize dedifferentiated liposarcomas with an inflammatory malignant fibrous histiocytoma component, Invitrogen MDM2 antibody (Zymed, clone IF2) was used in immunohistochemistry - frozen section on human samples at 1:100 (fig 3). J Pathol (2004) ncbi
mouse monoclonal (IF2)
  • immunohistochemistry - paraffin section; human
In order to report that most so-called malignant fibrous histiocytomas from the retroperitoneum are dedifferentiated liposarcoma, Invitrogen MDM2 antibody (Zymed, IF2) was used in immunohistochemistry - paraffin section on human samples . Mod Pathol (2003) ncbi
Abcam
mouse monoclonal (2A10)
  • western blot; human; loading ...; fig 1a
Abcam MDM2 antibody (Abcam, ab16895) was used in western blot on human samples (fig 1a). Aging (Albany NY) (2020) ncbi
mouse monoclonal (2A10)
  • immunoprecipitation; human; 1:200; loading ...; fig s4
  • immunocytochemistry; human; 1:200; loading ...; fig 4d
  • western blot; human; 1:1000; loading ...; fig s3
Abcam MDM2 antibody (Abcam, ab16895) was used in immunoprecipitation on human samples at 1:200 (fig s4), in immunocytochemistry on human samples at 1:200 (fig 4d) and in western blot on human samples at 1:1000 (fig s3). Oncogene (2019) ncbi
domestic rabbit monoclonal
  • western blot; human; 1:1000; loading ...; fig 4e
Abcam MDM2 antibody (Abcam, ab170880) was used in western blot on human samples at 1:1000 (fig 4e). Oncogene (2019) ncbi
mouse monoclonal (SMP 14)
  • western blot; human; fig 4c
Abcam MDM2 antibody (Abcam, ab3110) was used in western blot on human samples (fig 4c). iScience (2019) ncbi
mouse monoclonal (2A10)
  • western blot; mouse; loading ...; fig 1d
Abcam MDM2 antibody (Abcam, ab16895) was used in western blot on mouse samples (fig 1d). Cancer Cell (2017) ncbi
mouse monoclonal (2A10)
  • western blot; human; loading ...; fig 2b
Abcam MDM2 antibody (Abcam, ab16895) was used in western blot on human samples (fig 2b). Nucleic Acids Res (2017) ncbi
mouse monoclonal (2A10)
  • western blot; mouse; 1:400; loading ...; fig 2a
Abcam MDM2 antibody (Abcam, ab16895) was used in western blot on mouse samples at 1:400 (fig 2a). Int J Cancer (2017) ncbi
mouse monoclonal (2A10)
  • immunoprecipitation; human; loading ...; fig 8a
In order to study the anti-cancer activity and cytotoxicity of acrolein, Abcam MDM2 antibody (Abcam, ab16895) was used in immunoprecipitation on human samples (fig 8a). Oncotarget (2016) ncbi
mouse monoclonal (2A10)
  • western blot; human; loading ...; fig 7d
Abcam MDM2 antibody (Abcam, 2A10) was used in western blot on human samples (fig 7d). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (SMP 14)
  • western blot; rat; 1:1000; fig 5
Abcam MDM2 antibody (Abcam, ab3110) was used in western blot on rat samples at 1:1000 (fig 5). Nat Commun (2016) ncbi
mouse monoclonal (2A10)
  • western blot; human; loading ...; fig 5
Abcam MDM2 antibody (Abcam, ab16895) was used in western blot on human samples (fig 5). Nucleic Acids Res (2016) ncbi
mouse monoclonal (SMP 14)
  • western blot; mouse; fig 5
Abcam MDM2 antibody (Abcam, ab3110) was used in western blot on mouse samples (fig 5). Oncotarget (2015) ncbi
mouse monoclonal (SMP 14)
  • immunohistochemistry; mouse; loading ...; fig 4a
Abcam MDM2 antibody (Abcam, SMP14) was used in immunohistochemistry on mouse samples (fig 4a). Cell Death Differ (2015) ncbi
mouse monoclonal (SMP 14)
  • immunohistochemistry; human; 1:1000; loading ...; fig 1
Abcam MDM2 antibody (Abcam, ab3110) was used in immunohistochemistry on human samples at 1:1000 (fig 1). Oncol Lett (2015) ncbi
mouse monoclonal (SMP 14)
  • immunocytochemistry; rat; 1:200
  • western blot; rat
Abcam MDM2 antibody (Abcam, ab3110) was used in immunocytochemistry on rat samples at 1:200 and in western blot on rat samples . Mol Biol Cell (2012) ncbi
Bio-Rad
mouse monoclonal (SMP14)
  • western blot; rat; fig 1
Bio-Rad MDM2 antibody (AbDserotec, MCA1709) was used in western blot on rat samples (fig 1). PLoS ONE (2015) ncbi
Cell Signaling Technology
monoclonal (D1V2Z)
  • western blot; human; loading ...; fig 2j
Cell Signaling Technology MDM2 antibody (CST, 86,934) was used in western blot on human samples (fig 2j). Mol Cancer (2021) ncbi
monoclonal (D1V2Z)
  • western blot; human; 1:5000; loading ...; fig 3a
Cell Signaling Technology MDM2 antibody (Cell Signaling Technology, 86934) was used in western blot on human samples at 1:5000 (fig 3a). Clin Transl Med (2021) ncbi
monoclonal (D1V2Z)
  • western blot; mouse; loading ...; fig 5h
Cell Signaling Technology MDM2 antibody (Cell Signaling Technology, 86934) was used in western blot on mouse samples (fig 5h). Cell Death Dis (2021) ncbi
monoclonal (D1V2Z)
  • western blot; human; loading ...; fig 3c
Cell Signaling Technology MDM2 antibody (Cell Signaling, 86934) was used in western blot on human samples (fig 3c). Breast Cancer Res (2021) ncbi
monoclonal (D1V2Z)
  • western blot; human; loading ...; fig 4c
Cell Signaling Technology MDM2 antibody (cell signaling technology, 86934) was used in western blot on human samples (fig 4c). Front Oncol (2020) ncbi
monoclonal (D1V2Z)
  • immunocytochemistry; human; 0.2 ug/ml; loading ...; fig s5
  • western blot; human; 0.2 ug/ml; loading ...; fig 7e
Cell Signaling Technology MDM2 antibody (Cell Signaling, 86934) was used in immunocytochemistry on human samples at 0.2 ug/ml (fig s5) and in western blot on human samples at 0.2 ug/ml (fig 7e). Commun Biol (2020) ncbi
monoclonal (D1V2Z)
  • western blot; human; loading ...; fig 3b
Cell Signaling Technology MDM2 antibody (Cell Signaling Technologies, 86934) was used in western blot on human samples (fig 3b). Nat Commun (2018) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; fig 9a
Cell Signaling Technology MDM2 antibody (Cell Signaling Technology, 3521) was used in immunohistochemistry - paraffin section on mouse samples (fig 9a). J Exp Med (2018) ncbi
domestic rabbit polyclonal
  • other; human; loading ...; fig 4c
Cell Signaling Technology MDM2 antibody (Cell Signaling, 3521) was used in other on human samples (fig 4c). Cancer Cell (2018) ncbi
domestic rabbit polyclonal
  • western blot; mouse; 1:500; fig 5a
  • western blot; human; 1:500; loading ...; fig 5b
In order to show that PP1alpha inhibits the ubiquitin ligase Mdm2 by dephosphorylation to prevent its interaction with the mineralocorticoid receptor, Cell Signaling Technology MDM2 antibody (Cell Signaling, 3521) was used in western blot on mouse samples at 1:500 (fig 5a) and in western blot on human samples at 1:500 (fig 5b). Mol Cell Endocrinol (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:1000; fig 1h
In order to demonstrate that IGF2 secreted by inhibitor of differentiation-overexpressing oesophageal cancer cells instigates VEGFR1-positive bone marrow cells in the tumor macroenvironment, Cell Signaling Technology MDM2 antibody (Cell Signaling Technology, 3521) was used in western blot on human samples at 1:1000 (fig 1h). Nat Commun (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 2
In order to report the effects of NVP-CGM097 on the p53wildtype GOT1 cells, Cell Signaling Technology MDM2 antibody (Cell Signaling, 3521) was used in western blot on human samples (fig 2). Neuroendocrinology (2018) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 7e
Cell Signaling Technology MDM2 antibody (cell signalling, 3521) was used in western blot on human samples (fig 7e). EMBO Mol Med (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; fig 3f
Cell Signaling Technology MDM2 antibody (Cell Signaling, 3521) was used in western blot on human samples (fig 3f). PLoS ONE (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; fig 4e
Cell Signaling Technology MDM2 antibody (Cell Signaling, 3521) was used in western blot on human samples (fig 4e). J Biol Chem (2016) ncbi
domestic rabbit polyclonal
  • western blot; mouse; fig 4
Cell Signaling Technology MDM2 antibody (Cell Signaling Technology, 3521) was used in western blot on mouse samples (fig 4). Oncogene (2016) ncbi
BD Biosciences
mouse monoclonal (SMP14)
  • western blot; mouse; fig 2
BD Biosciences MDM2 antibody (BD Pharmingen, 556353) was used in western blot on mouse samples (fig 2). Cell Rep (2016) ncbi
mouse monoclonal (SMP14)
  • western blot; mouse
BD Biosciences MDM2 antibody (BD Biosciences, 556353) was used in western blot on mouse samples . Int J Cancer (2013) ncbi
MilliporeSigma
mouse monoclonal (HDM2-323)
  • immunoprecipitation; human; loading ...; fig 1c
  • western blot; human; loading ...; fig 3c
MilliporeSigma MDM2 antibody (Sigma, HDM2-323) was used in immunoprecipitation on human samples (fig 1c) and in western blot on human samples (fig 3c). Oncogene (2019) ncbi
mouse monoclonal (SMP14)
  • western blot; human; loading ...; fig 1c
MilliporeSigma MDM2 antibody (Sigma, SMP1) was used in western blot on human samples (fig 1c). Oncogene (2017) ncbi
Articles Reviewed
  1. Kumar D, Das M, Oberg A, Sahoo D, Wu P, Sauceda C, et al. Hepatocyte Deletion of IGF2 Prevents DNA Damage and Tumor Formation in Hepatocellular Carcinoma. Adv Sci (Weinh). 2022;9:e2105120 pubmed publisher
  2. Liu X, Liu Y, Liu Z, Lin C, Meng F, Xu L, et al. CircMYH9 drives colorectal cancer growth by regulating serine metabolism and redox homeostasis in a p53-dependent manner. Mol Cancer. 2021;20:114 pubmed publisher
  3. Kanellis D, Espinoza J, Zisi A, Sakkas E, Bartkova J, Katsori A, et al. The exon-junction complex helicase eIF4A3 controls cell fate via coordinated regulation of ribosome biogenesis and translational output. Sci Adv. 2021;7: pubmed publisher
  4. Sakai H, Kawakami H, Teramura T, Onodera Y, Somers E, Furuuchi K, et al. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. Clin Transl Med. 2021;11:e454 pubmed publisher
  5. Zheng H, Xu W, Zhou W, Yang R, Chen P, Liu T, et al. Beraprost ameliorates postmenopausal osteoporosis by regulating Nedd4-induced Runx2 ubiquitination. Cell Death Dis. 2021;12:497 pubmed publisher
  6. Loureiro J, Raimundo L, Calheiros J, Carvalho C, Barcherini V, Lima N, et al. Targeting p53 for Melanoma Treatment: Counteracting Tumour Proliferation, Dissemination and Therapeutic Resistance. Cancers (Basel). 2021;13: pubmed publisher
  7. Gao L, Zhu D, Wang Q, Bao Z, Yin S, Qiang H, et al. Proteome Analysis of USP7 Substrates Revealed Its Role in Melanoma Through PI3K/Akt/FOXO and AMPK Pathways. Front Oncol. 2021;11:650165 pubmed publisher
  8. Li H, Liu Y, Jiang W, Xue J, Cheng Y, Wang J, et al. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma. BMC Cancer. 2021;21:318 pubmed publisher
  9. Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, et al. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res. 2021;23:29 pubmed publisher
  10. Su S, Li Q, Zhang M, Zhang P, Shen H, Zhang C. An E2F1/DDX11/EZH2 Positive Feedback Loop Promotes Cell Proliferation in Hepatocellular Carcinoma. Front Oncol. 2020;10:593293 pubmed publisher
  11. Liu S, Tian Y, Zheng Y, Cheng Y, Zhang D, Jiang J, et al. TRIM27 acts as an oncogene and regulates cell proliferation and metastasis in non-small cell lung cancer through SIX3-β-catenin signaling. Aging (Albany NY). 2020;12:25564-25580 pubmed publisher
  12. Sola M, Magrin C, Pedrioli G, Pinton S, Salvade A, Papin S, et al. Tau affects P53 function and cell fate during the DNA damage response. Commun Biol. 2020;3:245 pubmed publisher
  13. Gain C, Malik S, Bhattacharjee S, Ghosh A, Robertson E, Das B, et al. Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway. PLoS Pathog. 2020;16:e1008105 pubmed publisher
  14. Sun B, Zhao X, Ming J, Liu X, Liu D, Jiang C. Stepwise detection and evaluation reveal miR-10b and miR-222 as a remarkable prognostic pair for glioblastoma. Oncogene. 2019;38:6142-6157 pubmed publisher
  15. Du T, Li H, Fan Y, Yuan L, Guo X, Zhu Q, et al. The deubiquitylase OTUD3 stabilizes GRP78 and promotes lung tumorigenesis. Nat Commun. 2019;10:2914 pubmed publisher
  16. Patel N, Wang J, Shiozawa K, Jones K, Zhang Y, Prokop J, et al. HDAC2 Regulates Site-Specific Acetylation of MDM2 and Its Ubiquitination Signaling in Tumor Suppression. iScience. 2019;13:43-54 pubmed publisher
  17. Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson F, et al. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 2019;35:204-220.e9 pubmed publisher
  18. Liu B, Yi J, Yang X, Liu L, Lou X, Zhang Z, et al. MDM2-mediated degradation of WRN promotes cellular senescence in a p53-independent manner. Oncogene. 2019;38:2501-2515 pubmed publisher
  19. Kim M, Song J, Koh D, Kim J, Hatano M, Jeon B, et al. Reciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression. J Biol Chem. 2019;294:299-313 pubmed publisher
  20. Hirano S, Udagawa O, Kobayashi Y, Kato A. Solubility changes of promyelocytic leukemia (PML) and SUMO monomers and dynamics of PML nuclear body proteins in arsenite-treated cells. Toxicol Appl Pharmacol. 2018;360:150-159 pubmed publisher
  21. Tajan M, Hock A, Blagih J, Robertson N, Labuschagne C, Kruiswijk F, et al. A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3. Cell Metab. 2018;28:721-736.e6 pubmed publisher
  22. Klein M, Dickson M, Antonescu C, Qin L, Dooley S, Barlas A, et al. PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene. 2018;37:5066-5078 pubmed publisher
  23. Ng S, Yoshida N, Christie A, Ghandi M, Dharia N, Dempster J, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9:2024 pubmed publisher
  24. Parisotto M, Grelet E, El Bizri R, Dai Y, Terzic J, Eckert D, et al. PTEN deletion in luminal cells of mature prostate induces replication stress and senescence in vivo. J Exp Med. 2018;215:1749-1763 pubmed publisher
  25. Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed publisher
  26. Huang C, Wu S, Ji H, Yan X, Xie Y, Murai S, et al. Identification of XBP1-u as a novel regulator of the MDM2/p53 axis using an shRNA library. Sci Adv. 2017;3:e1701383 pubmed publisher
  27. Mello S, Valente L, Raj N, Seoane J, Flowers B, McClendon J, et al. A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Cancer Cell. 2017;32:460-473.e6 pubmed publisher
  28. Periyasamy M, Singh A, Gemma C, Kranjec C, Farzan R, Leach D, et al. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells. Nucleic Acids Res. 2017;45:11056-11069 pubmed publisher
  29. Giono L, Resnick Silverman L, Carvajal L, St Clair S, Manfredi J. Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase. Oncogene. 2017;36:6762-6773 pubmed publisher
  30. Nagarajan S, Vohra T, Loffing J, Faresse N. Protein Phosphatase 1α enhances renal aldosterone signaling via mineralocorticoid receptor stabilization. Mol Cell Endocrinol. 2017;450:74-82 pubmed publisher
  31. Lee T, Pelletier J. Dependence of p53-deficient cells on the DHX9 DExH-box helicase. Oncotarget. 2017;8:30908-30921 pubmed publisher
  32. Xu W, Li B, Guan X, Chung S, Wang Y, Yip Y, et al. Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression. Nat Commun. 2017;8:14399 pubmed publisher
  33. Zhang Y, Zeng S, Hao Q, Lu H. Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner. Dev Biol. 2017;423:34-45 pubmed publisher
  34. Squillaro T, Antonucci I, Alessio N, Esposito A, Cipollaro M, Melone M, et al. Impact of lysosomal storage disorders on biology of mesenchymal stem cells: Evidences from in vitro silencing of glucocerebrosidase (GBA) and alpha-galactosidase A (GLA) enzymes. J Cell Physiol. 2017;232:3454-3467 pubmed publisher
  35. Worrall C, Suleymanova N, Crudden C, Trocoli Drakensjö I, Candrea E, Nedelcu D, et al. Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma. Oncogene. 2017;36:3274-3286 pubmed publisher
  36. Guan X, Lapak K, Hennessey R, Yu C, Shakya R, Zhang J, et al. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth. Mol Cancer Res. 2017;15:237-249 pubmed publisher
  37. Ren Z, Aerts J, Vandenplas H, Wang J, Gorbenko O, Chen J, et al. Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2. Cell Death Dis. 2016;7:e2560 pubmed publisher
  38. Reuther C, Heinzle V, Nölting S, Herterich S, Hahner S, Halilovic E, et al. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology. 2018;106:1-19 pubmed publisher
  39. Tian X, Dai S, Sun J, Jiang S, Sui C, Meng F, et al. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53. Cell Physiol Biochem. 2016;39:2088-2098 pubmed
  40. Kucab J, Hollstein M, Arlt V, Phillips D. Nutlin-3a selects for cells harbouring TP53 mutations. Int J Cancer. 2017;140:877-887 pubmed publisher
  41. Qi D, Cobrinik D. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation. Oncogene. 2017;36:1760-1769 pubmed publisher
  42. Wang H, Chen T, Weng C, Yang C, Tang M. Acrolein preferentially damages nucleolus eliciting ribosomal stress and apoptosis in human cancer cells. Oncotarget. 2016;7:80450-80464 pubmed publisher
  43. Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, et al. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines. Clin Exp Ophthalmol. 2017;45:288-296 pubmed publisher
  44. Liu T, Xiong J, Yi S, Zhang H, Zhou S, Gu L, et al. FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2. Oncogene. 2017;36:1678-1686 pubmed publisher
  45. Bauer M, Joerger A, Fersht A. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A. 2016;113:E5271-80 pubmed publisher
  46. Clay M, Martinez A, Weiss S, Edgar M. MDM2 and CDK4 Immunohistochemistry: Should It Be Used in Problematic Differentiated Lipomatous Tumors?: A New Perspective. Am J Surg Pathol. 2016;40:1647-1652 pubmed
  47. Riascos Bernal D, Chinnasamy P, Cao L, Dunaway C, Valenta T, Basler K, et al. β-Catenin C-terminal signals suppress p53 and are essential for artery formation. Nat Commun. 2016;7:12389 pubmed publisher
  48. Luo H, Cowen L, Yu G, Jiang W, Tang Y. SMG7 is a critical regulator of p53 stability and function in DNA damage stress response. Cell Discov. 2016;2:15042 pubmed publisher
  49. Ma T, Fan B, Zhang C, Zhao H, Han C, Gao C, et al. Metabonomics applied in exploring the antitumour mechanism of physapubenolide on hepatocellular carcinoma cells by targeting glycolysis through the Akt-p53 pathway. Sci Rep. 2016;6:29926 pubmed publisher
  50. Janer A, Prudent J, Paupe V, Fahiminiya S, Majewski J, Sgarioto N, et al. SLC25A46 is required for mitochondrial lipid homeostasis and cristae maintenance and is responsible for Leigh syndrome. EMBO Mol Med. 2016;8:1019-38 pubmed publisher
  51. Wei T, Biskup E, Gjerdrum L, Niazi O, Ødum N, Gniadecki R. Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma. Oncotarget. 2016;7:48391-48400 pubmed publisher
  52. York D, Withers S, Watson K, Seo K, Rebhun R. Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53. Vet Comp Oncol. 2017;15:1087-1100 pubmed publisher
  53. Chesnokova V, Zonis S, Zhou C, Recouvreux M, Ben Shlomo A, Araki T, et al. Growth hormone is permissive for neoplastic colon growth. Proc Natl Acad Sci U S A. 2016;113:E3250-9 pubmed publisher
  54. Stepanenko A, Andreieva S, Korets K, Mykytenko D, Baklaushev V, Huleyuk N, et al. Temozolomide promotes genomic and phenotypic changes in glioblastoma cells. Cancer Cell Int. 2016;16:36 pubmed publisher
  55. Ho T, Guilbaud G, Blow J, Sale J, Watson C. The KRAB Zinc Finger Protein Roma/Zfp157 Is a Critical Regulator of Cell-Cycle Progression and Genomic Stability. Cell Rep. 2016;15:724-734 pubmed publisher
  56. Chen Y, Pan K, Wang P, Cao Z, Wang W, Wang S, et al. HBP1-mediated Regulation of p21 Protein through the Mdm2/p53 and TCF4/EZH2 Pathways and Its Impact on Cell Senescence and Tumorigenesis. J Biol Chem. 2016;291:12688-705 pubmed publisher
  57. Hall A, Lu W, Godfrey J, Antonov A, Paicu C, Moxon S, et al. The cytoskeleton adaptor protein ankyrin-1 is upregulated by p53 following DNA damage and alters cell migration. Cell Death Dis. 2016;7:e2184 pubmed publisher
  58. Jin H, Lee K, Kim Y, Oh H, Maeng Y, Kim T, et al. Scaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells. Oncogene. 2016;35:5106-18 pubmed publisher
  59. Chen S, FORRESTER W, Lahav G. Schedule-dependent interaction between anticancer treatments. Science. 2016;351:1204-8 pubmed publisher
  60. Singh A, Joshi S, Zulcic M, Alcaraz M, GARLICH J, Morales G, et al. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS ONE. 2016;11:e0150836 pubmed publisher
  61. Nakayama R, Zhang Y, Czaplinski J, Anatone A, Sicinska E, Fletcher J, et al. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016;7:16581-92 pubmed publisher
  62. Swetzig W, Wang J, Das G. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. Oncotarget. 2016;7:16049-69 pubmed publisher
  63. Liu X, Tan Y, Zhang C, Zhang Y, Zhang L, Ren P, et al. NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2. EMBO Rep. 2016;17:349-66 pubmed publisher
  64. Xie X, Lozano G, Siddik Z. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene. 2016;35:4798-806 pubmed publisher
  65. Kwon D, Eom G, Ko J, Shin S, Joung H, Choe N, et al. MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification. Nat Commun. 2016;7:10492 pubmed publisher
  66. Chavoshi S, Egorova O, Lacdao I, Farhadi S, Sheng Y, Saridakis V. Identification of Kaposi Sarcoma Herpesvirus (KSHV) vIRF1 Protein as a Novel Interaction Partner of Human Deubiquitinase USP7. J Biol Chem. 2016;291:6281-91 pubmed publisher
  67. Ying M, Zhang L, Zhou Q, Shao X, Cao J, Zhang N, et al. The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα. Oncogene. 2016;35:4358-67 pubmed publisher
  68. Daniele S, Barresi E, Zappelli E, Marinelli L, Novellino E, Da Settimo F, et al. Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells. Oncotarget. 2016;7:7866-84 pubmed publisher
  69. Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo S, Low D, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest. 2016;126:68-84 pubmed publisher
  70. Ivanschitz L, Takahashi Y, Jollivet F, Ayrault O, Le Bras M, de Thé H. PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence. Proc Natl Acad Sci U S A. 2015;112:14278-83 pubmed publisher
  71. Waye S, Naeem A, Choudhry M, Parasido E, Tricoli L, Sivakumar A, et al. The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells. Aging (Albany NY). 2015;7:854-68 pubmed
  72. Ahn H, Kim K, Shin K, Lim K, Kim J, Lee J, et al. Ell3 stabilizes p53 following CDDP treatment via its effects on ubiquitin-dependent and -independent proteasomal degradation pathways in breast cancer cells. Oncotarget. 2015;6:44523-37 pubmed publisher
  73. Yu Z, Huang Y, Shieh S. Requirement for human Mps1/TTK in oxidative DNA damage repair and cell survival through MDM2 phosphorylation. Nucleic Acids Res. 2016;44:1133-50 pubmed publisher
  74. Tonsing Carter E, Bailey B, Saadatzadeh M, Ding J, Wang H, Sinn A, et al. Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model. Mol Cancer Ther. 2015;14:2850-63 pubmed publisher
  75. Ye M, Tang Y, Tang S, Liu J, Wu K, Yao S, et al. STIP is a critical nuclear scaffolding protein linking USP7 to p53-Mdm2 pathway regulation. Oncotarget. 2015;6:34718-31 pubmed publisher
  76. Kramer H, Lai C, Patel H, Periyasamy M, Lin M, Feller S, et al. LRH-1 drives colon cancer cell growth by repressing the expression of the CDKN1A gene in a p53-dependent manner. Nucleic Acids Res. 2016;44:582-94 pubmed publisher
  77. Saâda Bouzid E, Burel Vandenbos F, Ranchère Vince D, Birtwisle Peyrottes I, Chetaille B, Bouvier C, et al. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. Mod Pathol. 2015;28:1404-14 pubmed publisher
  78. Moussa R, Kovacevic Z, Richardson D. Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types. Oncotarget. 2015;6:29694-711 pubmed publisher
  79. Wang H, Lööf S, Borg P, Nader G, Blau H, Simon A. Turning terminally differentiated skeletal muscle cells into regenerative progenitors. Nat Commun. 2015;6:7916 pubmed publisher
  80. Haupt S, Buckley D, Pang J, Panimaya J, Paul P, Gamell C, et al. Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death Dis. 2015;6:e1821 pubmed publisher
  81. Jacquin S, Rincheval V, Mignotte B, Richard S, Humbert M, Mercier O, et al. Inactivation of p53 Is Sufficient to Induce Development of Pulmonary Hypertension in Rats. PLoS ONE. 2015;10:e0131940 pubmed publisher
  82. Wang J, Chen S, Sun C, Chien T, Chern Y. A central role of TRAX in the ATM-mediated DNA repair. Oncogene. 2016;35:1657-70 pubmed publisher
  83. Rueda Rincon N, Bloch K, Derua R, Vyas R, Harms A, Hankemeier T, et al. p53 attenuates AKT signaling by modulating membrane phospholipid composition. Oncotarget. 2015;6:21240-54 pubmed
  84. Wu H, Leng R. MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function. Oncotarget. 2015;6:21479-92 pubmed
  85. Scala F, Brighenti E, Govoni M, Imbrogno E, Fornari F, Treré D, et al. Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate. Oncogene. 2016;35:977-89 pubmed publisher
  86. Zhang W, Hou J, Wang X, Jiang R, Yin Y, Ji J, et al. PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis. Oncotarget. 2015;6:9420-33 pubmed
  87. Puzio Kuter A, Laddha S, Castillo Martin M, Sun Y, Cordon Cardo C, Chan C, et al. Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma. Cell Death Differ. 2015;22:1785-91 pubmed publisher
  88. Kovatcheva M, Liu D, Dickson M, Klein M, O Connor R, Wilder F, et al. MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget. 2015;6:8226-43 pubmed
  89. Weingertner N, Neuville A, Chibon F, Ray Coquard I, Marcellin L, Ghnassia J. Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report. Appl Immunohistochem Mol Morphol. 2015;23:230-5 pubmed publisher
  90. Righi A, Gambarotti M, Benini S, Gamberi G, Cocchi S, Picci P, et al. MDM2 and CDK4 expression in periosteal osteosarcoma. Hum Pathol. 2015;46:549-53 pubmed publisher
  91. Ortega P, Suster D, Falconieri G, Zambrano E, Moran C, Morrison C, et al. Liposarcomas of the posterior mediastinum: clinicopathologic study of 18 cases. Mod Pathol. 2015;28:721-31 pubmed publisher
  92. Kong L, Wei J, Haider A, Liebelt B, Ling X, Conrad C, et al. Therapeutic targets in subependymoma. J Neuroimmunol. 2014;277:168-75 pubmed publisher
  93. Zhang P, Wu S, Wang Y, Fan Z, Li C, Feng M, et al. p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study. Oncol Lett. 2015;9:113-118 pubmed
  94. Giovannini C, Minguzzi M, Baglioni M, Fornari F, Giannone F, Ravaioli M, et al. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. Oncotarget. 2014;5:10607-20 pubmed
  95. Vega Naredo I, Cunha Oliveira T, Serafim T, Sardao V, Oliveira P. Analysis of pro-apoptotic protein trafficking to and from mitochondria. Methods Mol Biol. 2015;1241:163-80 pubmed publisher
  96. Lee M, Marina M, King J, Saavedra H. Differential expression of centrosome regulators in Her2+ breast cancer cells versus non-tumorigenic MCF10A cells. Cell Div. 2014;9:3 pubmed publisher
  97. Idogawa M, Ohashi T, Sugisaka J, Sasaki Y, Suzuki H, Tokino T. Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells. Oncotarget. 2014;5:7540-8 pubmed
  98. Jacob A, Singh R, Comiskey D, Rouhier M, Mohammad F, Bebee T, et al. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways. PLoS ONE. 2014;9:e104444 pubmed publisher
  99. Suico M, Fukuda R, Miyakita R, Koyama K, Taura M, Shuto T, et al. The transcription factor MEF/Elf4 is dually modulated by p53-MDM2 axis and MEF-MDM2 autoregulatory mechanism. J Biol Chem. 2014;289:26143-54 pubmed publisher
  100. Hamilton G, Abraham A, Morton J, Sampson O, Pefani D, Khoronenkova S, et al. AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget. 2014;5:6142-67 pubmed
  101. Yamauchi T, Nishiyama M, Moroishi T, Yumimoto K, Nakayama K. MDM2 mediates nonproteolytic polyubiquitylation of the DEAD-Box RNA helicase DDX24. Mol Cell Biol. 2014;34:3321-40 pubmed publisher
  102. Kardos G, Dai M, Robertson G. Growth inhibitory effects of large subunit ribosomal proteins in melanoma. Pigment Cell Melanoma Res. 2014;27:801-12 pubmed publisher
  103. Thirunavukarasou A, Singh P, Govindarajalu G, Bandi V, Baluchamy S. E3 ubiquitin ligase Cullin4B mediated polyubiquitination of p53 for its degradation. Mol Cell Biochem. 2014;390:93-100 pubmed publisher
  104. Qi M, Zhang J, Zeng W, Chen X. DNAJB1 stabilizes MDM2 and contributes to cancer cell proliferation in a p53-dependent manner. Biochim Biophys Acta. 2014;1839:62-9 pubmed publisher
  105. Horiguchi M, Koyanagi S, Hamdan A, Kakimoto K, Matsunaga N, Yamashita C, et al. Rhythmic control of the ARF-MDM2 pathway by ATF4 underlies circadian accumulation of p53 in malignant cells. Cancer Res. 2013;73:2639-49 pubmed publisher
  106. Qiu H, Zhang L, Ren C, Zeng Z, Wu W, Luo H, et al. Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling. PLoS ONE. 2013;8:e56959 pubmed publisher
  107. Yakkioui Y, Temel Y, Creytens D, Jahanshahi A, Fleischeuer R, Santegoeds R, et al. A comparison of cell-cycle markers in skull base and sacral chordomas. World Neurosurg. 2014;82:e311-8 pubmed publisher
  108. Kazmi S, Byer S, Eckert J, Turk A, Huijbregts R, Brossier N, et al. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis. Am J Pathol. 2013;182:646-67 pubmed publisher
  109. Sarkar S, Brautigan D, Parsons S, Larner J. Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells. Oncogene. 2014;33:26-33 pubmed publisher
  110. Singh S, Ramamoorthy M, Vaughan C, Yeudall W, Deb S, Palit Deb S. Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells. Cell Death Differ. 2013;20:558-66 pubmed publisher
  111. Conradt L, Henrich A, Wirth M, Reichert M, Lesina M, Algül H, et al. Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death. Int J Cancer. 2013;132:2248-57 pubmed publisher
  112. Liu Y, Chen Y, Lu X, Wang Y, Duan Y, Cheng C, et al. SCYL1BP1 modulates neurite outgrowth and regeneration by regulating the Mdm2/p53 pathway. Mol Biol Cell. 2012;23:4506-14 pubmed publisher
  113. Yoshida A, Ushiku T, Motoi T, Beppu Y, Fukayama M, Tsuda H, et al. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. Am J Surg Pathol. 2012;36:423-31 pubmed publisher
  114. Dujardin F, Binh M, Bouvier C, Gomez Brouchet A, Larousserie F, Muret A, et al. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol. 2011;24:624-37 pubmed publisher
  115. Yoshida A, Ushiku T, Motoi T, Shibata T, Fukayama M, Tsuda H. Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant. Am J Surg Pathol. 2010;34:1361-6 pubmed publisher
  116. Yoshida A, Ushiku T, Motoi T, Shibata T, Beppu Y, Fukayama M, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. Mod Pathol. 2010;23:1279-88 pubmed publisher
  117. Horvai A, Devries S, Roy R, O Donnell R, Waldman F. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. Mod Pathol. 2009;22:1477-88 pubmed publisher
  118. Daugaard S, Christensen L, Høgdall E. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS. 2009;117:518-25 pubmed publisher
  119. Nahal A, Meterissian S. Lipoleiomyosarcoma of the rectosigmoid colon: a unique site for a rare variant of liposarcoma. Am J Clin Oncol. 2009;32:353-5 pubmed publisher
  120. Amiot A, Dokmak S, Sauvanet A, Vilgrain V, Bringuier P, Scoazec J, et al. Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion. JOP. 2008;9:339-45 pubmed
  121. Horvai A, Schaefer J, Nakakura E, O Donnell R. Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. Mod Pathol. 2008;21:517-24 pubmed publisher
  122. Bosco M, Allia E, Coindre J, Odasso C, Pagani A, Pacchioni D. alpha-fetoprotein expression in a dedifferentiated liposarcoma. Virchows Arch. 2006;448:517-20 pubmed
  123. Mentzel T, Toennissen J, Rutten A, Schaller J. Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location. Virchows Arch. 2005;446:300-4 pubmed
  124. Coindre J, Hostein I, Maire G, Derré J, Guillou L, Leroux A, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol. 2004;203:822-30 pubmed
  125. Coindre J, Mariani O, Chibon F, Mairal A, De Saint Aubain Somerhausen N, Favre Guillevin E, et al. Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. Mod Pathol. 2003;16:256-62 pubmed
  126. Calabrò V, Mansueto G, Parisi T, Vivo M, Calogero R, La Mantia G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J Biol Chem. 2002;277:2674-81 pubmed